Welcome to our dedicated page for Horizon Space Acquisition II SEC filings (Ticker: HSPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Horizon Space Acquisition II Corp. (HSPT) provide detailed insight into its activities as a Cayman Islands exempted special purpose acquisition company (SPAC) listed on Nasdaq. Through current reports on Form 8-K, annual reports on Form 10-K, and other submissions, the company discloses material agreements, financing arrangements, and progress toward completing its initial business combination.
For HSPT, key filings include Form 8-K reports describing unsecured promissory notes issued to its sponsor or sponsor designees. These notes bear no interest, are repayable upon the earlier of the consummation of a business combination or the expiry of the company’s term, and may be convertible into private units at a price referenced to $10.00 per unit. The filings explain the composition of these private units, which can include ordinary shares, rights to receive fractions of ordinary shares, and, in some cases, warrants.
Another important aspect of Horizon Space Acquisition II Corp.’s filings is the disclosure of its ability to extend the deadline to complete its initial business combination. The company’s charter allows for extensions when specified extension fees are deposited into the trust account for public shareholders. Form 8-K filings describe these extension payments and the related promissory notes, outlining how the SPAC manages its timeline to pursue a suitable transaction.
Filings also cover the definitive Business Combination Agreement with SL Bio Ltd. and the creation of SL Science Holding Limited (PubCo) as the proposed listed entity. Investors can review registration statements and proxy materials referenced in public announcements to understand the structure of the proposed mergers, the exchange of securities into PubCo ordinary shares, and the conditions required for closing.
On this page, users can access Horizon Space Acquisition II Corp.’s SEC filings as they are made available through EDGAR. AI-powered summaries can help explain complex sections of documents such as Form 8-K, Form 10-K, and registration statements, highlight the terms of promissory notes and extension arrangements, and clarify how the proposed business combination with SL Bio Ltd. is structured. Form 4 and related ownership filings, when present, can also be reviewed to understand changes in holdings of HSPT securities.
Horizon Space Acquisition II Corp. reports shareholder approvals that advance its planned merger with SL BIO Ltd. and extend its deadline to complete a business combination. Investors approved the business combination with SL Bio, related governance changes at PubCo, and the appointment of William Wang Ching-Dong as sole director effective at the first merger’s closing.
In a separate meeting, shareholders approved amendments to Horizon’s charter and trust agreement so the company can extend its February 18, 2026 termination date in up to twelve one‑month increments to February 18, 2027, funded by monthly deposits into the trust account of the lesser of $50,000 or $0.033 per remaining public share.
Horizon Space Acquisition II Corp. received an updated Schedule 13G/A (Amendment No. 3) from Bank of Montreal, Bank of Montreal Holding Inc., and BMO Nesbitt Burns Inc. stating that they now beneficially own 0 ordinary shares, representing 0% of the company’s ordinary shares.
The reporting entities disclose no sole or shared voting power and no sole or shared dispositive power over Horizon Space Acquisition II Corp. shares. They also indicate that they own 5 percent or less of the class, confirming that they are no longer significant shareholders and that any prior position has effectively been reduced to zero.
Horizon Space Acquisition II Corp. filed a Form 8-K describing additional proxy materials for its proposed business combination with SL BIO Ltd. and the creation of SL Science Holding Limited as the post‑merger public company (“PubCo”). The filing adds two independent director nominees, Joseph Levinson and Qian (Hebe) Xu, to PubCo’s expected board, expanding the slate to nine directors, including CEO and chairman William Wang Ching‑Dong.
The updated beneficial ownership table shows SL Link Holding Ltd., associated with William Wang, expected to hold 333,832,129 PubCo ordinary shares, representing 58.9% of voting power in a no‑redemption case and 59.6% under maximum redemptions. Qian Xu is expected to beneficially own 20,000 shares. The filing also confirms there is no change to the February 12, 2026 business combination meeting date, time, location, or record date, and includes a standard form of director offer letter covering term, cash fees, potential equity awards, confidentiality, IP ownership, non‑solicitation, and indemnification.
Horizon Space Acquisition II Corp. filed a current report describing added independent director nominees for SL Science Holding Limited, the post‑combination public company. Joseph Levinson and Qian (Hebe) Xu are expected to join PubCo’s board as independent directors, expanding governance experience in cross‑border listings and investment banking.
The filing updates the expected beneficial ownership table for PubCo after the business combination with SL BIO Ltd. William Wang is expected to beneficially own 333,832,129 PubCo ordinary shares, representing 58.9% of voting power in a no‑redemption scenario and 59.6% under maximum redemption. The business combination meeting schedule, record date, location, and redemption deadline are all reaffirmed with no changes.
Horizon Space Acquisition II Corp. filed additional proxy solicitation materials related to its proposed business combination with SL BIO Ltd., mainly updating governance and ownership details for the future combined company, SL Science Holding Limited (PubCo).
The filing adds two independent director nominees for PubCo, Joseph Levinson and Qian (Hebe) Xu, and updates the post-closing beneficial ownership table. In the no-redemption scenario, PubCo is expected to have 566,591,350 ordinary shares outstanding, with William Wang beneficially owning 333,832,129 shares, representing 58.9% of PubCo’s voting power.
In the maximum redemption scenario, PubCo is expected to have 559,956,923 ordinary shares outstanding, with William Wang’s voting power at 59.6%. The meeting date, time, location, record date, and redemption deadline for the February 12, 2026 Business Combination Meeting remain unchanged.
Horizon Space Acquisition II Corp. (HSPT) filed an 8-K to supplement its proxy materials for the February 12, 2026 business combination meeting with SL BIO Ltd. The update mainly adds two independent director nominees for the post-merger public company, SL Science Holding Limited (PubCo): Joseph Levinson and Qian (Hebe) Xu.
The filing also refreshes the expected beneficial ownership table for PubCo. Assuming 566,591,350 ordinary shares outstanding in a no-redemption scenario (and 559,956,923 in a maximum-redemption scenario), SL Link Holding Ltd., associated with William Wang, is expected to hold 333,832,129 shares, representing about 58.9% to 59.6% of PubCo’s voting power. Qian Xu is expected to beneficially own 20,000 shares.
The schedule and logistics for the business combination meeting remain unchanged. The meeting is set for 9:00 a.m. Eastern Time on February 12, 2026, with a redemption deadline of 5:00 p.m. Eastern Time on February 10, 2026, and shareholders of record as of December 29, 2025 remain entitled to vote.
Horizon Space Acquisition II Corp. is clarifying how public shareholders can redeem their shares around two key shareholder meetings tied to its proposed business combination with SL BIO Ltd. and a potential deadline extension.
The company explains that investors who already elected redemption for the February 12, 2026 Business Combination Meeting and want their shares redeemed whether the merger closes or the extension is approved must also instruct the transfer agent to redeem in connection with the Extension Proposals by 5:00 p.m. Eastern Time on February 11, 2026. If the Extension Meeting on February 13, 2026 is not held or the Extension Proposals are not implemented, those shares will instead be redeemed if the business combination is consummated, unless the shareholder withdraws the request.
The filing confirms there is no change to the Business Combination Meeting’s time, location, record date, or proposals, and reminds shareholders of the February 10, 2026 redemption deadline for that meeting and that record-date holders can vote even if they later sell their shares.
Horizon Space Acquisition II Corp. filed an update explaining how public shareholders can redeem their shares around its proposed business combination with SL BIO Ltd. and a related deadline extension vote. The company clarifies that investors who already requested redemption for the business combination must also submit instructions for the extension vote if they want redemptions to apply in either outcome.
The filing confirms there is no change to the date, time, location, or record date for the February 12, 2026 business combination meeting, and repeats the February 10, 2026 and February 11, 2026 redemption deadlines. It also highlights that the extension meeting on February 13, 2026 may not occur and outlines how that would affect redemption elections.
Horizon Space Acquisition II Corp. is updating shareholders on how to redeem shares around its proposed merger with SL BIO Ltd. and a possible deadline extension. The company explains that public shareholders who already elected to redeem for the February 12, 2026 Business Combination Meeting must also instruct the transfer agent to redeem in connection with the February 13, 2026 Extension Meeting by 5:00 p.m. Eastern Time on February 11, 2026 if they want redemption to apply whether the merger closes or the extension is approved.
Horizon notes that if the Extension Meeting is not held and the extension is not implemented, shares submitted for redemption for both meetings will be redeemed upon consummation of the Business Combination unless the request is withdrawn, while shares redeemed only for the Extension Meeting would not be redeemed in that scenario. The company confirms there is no change to the time, location, record date, purpose, or proposals for the Business Combination Meeting and reminds shareholders that related proxy and registration materials are available through the SEC.
Horizon Space Acquisition II Corp. filed an 8-K describing a press release that clarifies how public shareholders can redeem their shares around its proposed business combination with SL BIO Ltd. and related extension proposals.
Shareholders who already submitted redemption requests for the February 12, 2026 Business Combination Meeting and want their public shares redeemed whether the business combination closes or the extension is approved must instruct the transfer agent to redeem those shares for the Extension Proposals by 5:00 p.m. Eastern Time on February 11, 2026.
If the Extension Meeting on February 13, 2026 is not held and the Extension Proposals are not implemented, any shares submitted for redemption for both meetings will be redeemed upon consummation of the business combination unless the holder withdraws the request. The filing confirms there is no change to the time, location, record date or proposals for the Business Combination Meeting.